US Patent

US8835501 — Pharmaceutical formulations of HDAC inhibitors

Formulation · Assigned to Topotarget UK Ltd · Expires 2027-10-27 · 1y remaining

Vulnerability score 60/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects pharmaceutical compositions containing certain carbamic acid compounds, such as PXD-101, in combination with ingredients like cyclodextrin, arginine, and meglumine.

USPTO Abstract

This invention pertains to pharmaceutical compositions comprising certain carbamic acid compounds (e.g., which inhibit HDAC (histone deacetylase) activity) (e.g., PXD-101, N hydroxy-3-(3-phenylsulfamoyl-phenyl)-acrylamide)) and one or more additional ingredients selected from cyclodextrin, arginine, and meglumine. The present invention also pertains to the use of such compositions, for example, in the inhibition of HDAC, and in the treatment of conditions mediated by HDAC, cancer, proliferative conditions, psoriasis, etc.

Drugs covered by this patent

Patent Metadata

Patent number
US8835501
Jurisdiction
US
Classification
Formulation
Expires
2027-10-27
Drug substance claim
No
Drug product claim
Yes
Assignee
Topotarget UK Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.